uniQure (QURE) Q1 2026 earnings snapshot

uniQure (QURE) opened 2026 with Q1 revenue of US$3.6 million and a basic EPS loss of US$0.85, alongside a net loss of US$53.5 million, putting fresh numbers behind a stock that last closed at US$22.82. The company has seen quarterly revenue move from US$1.6 million in Q1 2025 to US$3.6 million in Q1 2026, while basic EPS has tracked losses between US$0.59 and US$1.38 over recent quarters, and trailing twelve month EPS sat at a loss of US$3.49 on revenue of US$18.1 million in the latest period. For investors, the focus this quarter is on how a modest top line compares with sizeable ongoing losses and what that means for margins as the business works through its pipeline.

See our full analysis for uniQure.

With the latest figures on the table, the next step is to see how these results line up with the widely followed narratives around growth potential, risk, and long term profitability.

US$208.9m trailing loss keeps profitability distant

• On a trailing twelve month basis, uniQure reported US$18.1 million in revenue against a net loss of US$208.9 million and a basic EPS loss of US$3.49.
• Bears focus on the fact that losses have grown at about 42.4% per year over five years and see the forecast for continued losses over at least the next three years as a key concern.
  • That concern lines up with the recent quarterly pattern, where net loss has stayed in the US$37 million to US$81 million range since early 2025, despite revenue fluctuating between US$3.6 million and US$5.6 million.
  • Analysts expecting ongoing unprofitability argue that even if revenue grows, the current scale of the loss relative to US$18.1 million of trailing revenue keeps the path to positive earnings uncertain.

Bears warn that heavy cash burn against a small revenue base leaves little room for error if trial costs rise or timelines stretch, which is central to the cautious story around AMT-130 and the broader pipeline. 🐻 uniQure Bear Case

Revenue growth expectations clash with recent top line

• While trailing twelve month revenue is US$18.1 million, analysts are referencing forecast revenue growth of about 54% a year from this base, even as Q1 2026 revenue sits at US$3.6 million versus US$5.6 million in Q4 2025.
• Bulls point to programs like AMT-130 and other gene therapies as potential drivers of very rapid revenue expansion, yet the recent numbers underline how early the commercial story still is.
  • Supporters emphasize that a strong Huntington's disease dataset and multiple early stage programs could expand the revenue opportunity far beyond the current US$3.6 million quarterly run rate.
  • At the same time, the five quarter history provided shows revenue moving within a narrow band of roughly US$1.6 million to US$5.6 million, which challenges the bullish idea that growth momentum is already visible in reported sales.

Bulls argue that the gap between today’s small revenue base and the growth story on AMT-130 is exactly where long term upside could come from if approvals land and adoption follows. 🐂 uniQure Bull Case

Valuation and volatility with a US$22.82 share price

• At a share price of US$22.82 and a P/B of 9.6x, the stock screens cheaper than peers at 22.5x but more expensive than the wider US Biotech group at 2.3x, against a backdrop of highly volatile trading over the past three months.
• Critics highlight that this valuation sits on top of recent shareholder dilution and insider selling, which they see as a signal that management and the market are still wrestling with the trade off between funding large losses and the long term payoff from the pipeline.
  • The mix of higher than industry P/B, trailing twelve month net loss of US$208.9 million and no profitability forecast in the next three years explains why some investors question how much of the growth story is already reflected in the price.
  • At the same time, the discount to peer P/B levels can be read as the market pricing in the risks around clinical timelines, regulatory decisions and share price swings rather than assuming a best case outcome.

Next Steps

To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for uniQure on Simply Wall St. Add the company to your watchlist or portfolio so you'll be alerted when the story evolves.

With sentiment clearly split between cautious and optimistic, now is a good time to look through the figures yourself and decide where you stand, starting with 1 key reward and 4 important warning signs

See What Else Is Out There

uniQure is working from a small US$18.1 million revenue base against a recent US$208.9 million trailing loss and ongoing forecasting of losses.

If that mix of sizable losses and uncertainty around the path to profitability feels uncomfortable, you can quickly focus on steadier ideas using the 74 resilient stocks with low risk scores.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.